Reuters logo
BRIEF-Abivax’S ABX464 reduces HIV reservoir in blood in second phase 2a clinical trial
September 28, 2017 / 5:42 AM / in 3 months

BRIEF-Abivax’S ABX464 reduces HIV reservoir in blood in second phase 2a clinical trial

Sept 28 (Reuters) - ABIVAX SA

* ABIVAX’S ABX464 REDUCES HIV RESERVOIR IN BLOOD IN SECOND PHASE 2A CLINICAL TRIAL

* ‍ABX464 SIGNIFICANTLY REDUCED HIV VIRAL RESERVOIR IN BLOOD IN PATIENTS WITH HIV​

* ‍DATA CONFIRM AND EXTEND HIV RESERVOIR REDUCTION BY ABX464 SEEN IN ABIVAX‘S PREVIOUS PHASE 2A TRIAL, ABX464-004.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below